HELP
Cybin Inc
NASDAQ · Pharmaceuticals
$5.98
+0.12 (+2.05%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 493.3K | 481.3K | 473.6K |
| Net Income | 115.4K | 80.6K | 101.2K |
| EPS | — | — | — |
| Profit Margin | 23.4% | 16.8% | 21.4% |
| Rev Growth | +17.7% | -1.9% | +10.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 171.8K | 222.1K | 176.9K |
| Total Equity | 1.50M | 1.44M | 1.63M |
| D/E Ratio | 0.11 | 0.15 | 0.11 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 189.6K | 155.0K | 161.9K |
| Free Cash Flow | 102.8K | 100.3K | 125.4K |